Skip to content

A comparison of two pain relief injections (tramadol and pentazocine) for women in labour in Enugu,Nigeria.

A randomised controlled trial comparing intramuscular tramadol versus intramuscular pentazocine for labour analgesia in Enugu,Nigeria.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
PACTR
Registry ID
PACTR202604757190219
Enrollment
330
Registered
2026-04-24
Start date
2026-07-10
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Diseases Pregnancy and Childbirth Respiratory Analgesia in labour Anaesthesia

Interventions

tramadol

Sponsors

Philip Ikechukwu Ugota
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: • Primigravid or multigravid women in active labour (cervical dilatation 4-8 cm). • Gestational age of 37--42 weeks. • Singleton pregnancy with a cephalic presentation. • Pain score of 5 on a 10-point Visual Analogue Scale requesting pain relief. • Haemodynamically stable. • Age 18-44 years. • Ability to understand and provide informed consent.

Exclusion criteria

Exclusion criteria: • Known allergy or contraindication to tramadol or pentazocine. • Known opioid dependence or chronic opioid use. • Pre-existing medical conditions (e.g., severe cardiac, renal, hepatic, or neurological disease, uncontrolled hypertension, pre-eclampsia, eclampsia, or gestational diabetes requiring insulin) that might affect drug metabolism or neonatal outcomes. • Any obstetric complications (e.g., antepartum haemorrhage, placenta praevia, abruptio placentae, severe intrauterine growth restriction, chorioamnionitis). • Evidence of foetal distress requiring immediate intervention. • History of psychiatric illness or known psychotomimetic tendencies. • Contraindication to intramuscular injections. • Women who have received any systemic analgesia or regional analgesia during the current labour.

Design outcomes

Primary

MeasureTime frame
. Primary Outcome Measure: •Analgesic Efficacy: Measured by changes in pain intensity using a 10-point VAS at baseline, 15, 30, 60, 90, and 120 minutes post-administration, and hourly thereafter until delivery. Total pain relief and peak pain relief will also be assessed.

Secondary

MeasureTime frame
Secondary Outcome Measures: • Maternal Adverse Effects: Incidence and severity of adverse effects (e.g., nausea, vomiting, dizziness, sedation using a sedation score, pruritus, psychotomimetic effects like dysphoria or hallucinations) recorded hourly for 4 hours post-administration.

Countries

Nigeria

Contacts

Public ContactAnthony Nweze

Senior Registrar Department of Obstetrics and Gynaecology University of Nigeria teaching Hospital Ituku Ozalla Enugu

nwezeanthony85@gmail.com07035924830

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026